TNFA

TNF Pharmaceuticals, Inc. (TNFA)

$3.68

Last Close (24-hour delay)

PASS

• BUY Advisory
• SELL Advisory (Profit)​
• SELL Advisory (Loss)​

• Profit
• Loss
• Pass (Skip investing)

Stock price based on last close

*as per simulation
(see disclosures)

Upturn Star Rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock

Historic Profit -37.68%

Avg. Invested days 10

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance 1.0

Stock Returns Performance 1.0

Profits based on simulation

Last Close 10/10/2025

Upturn AI SWOT

TNF Pharmaceuticals, Inc.

Company Overview

History and Background

TNF Pharmaceuticals, Inc. appears to be a fictitious company. Consequently, detailed historical information is unavailable.

Core Business Areas

• Segment Name 1: Since TNF Pharmaceuticals, Inc. is fictitious, no real business segments exist.

Leadership and Structure

As a fictitious company, no real leadership or organizational structure exists.

Top Products and Market Share

Key Offerings

• Product Name 1: Being a fictitious company, no products or market share data are available.

Market Dynamics

Industry Overview

Without a real company, no industry context can be accurately provided.

Positioning

TNF Pharmaceuticals, Inc., being fictitious, lacks any market positioning.

Total Addressable Market (TAM)

N/A

Upturn SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Competitors and Market Share

Key Competitors

Competitive Landscape

N/A

Growth Trajectory and Initiatives

Historical Growth: N/A

Future Projections: N/A

Recent Initiatives: N/A

Summary

TNF Pharmaceuticals, Inc. is a fictitious entity, rendering a meaningful analysis impossible. No business operations, market position, or financial data are available. Therefore, no informed conclusion can be drawn regarding its strengths, weaknesses, opportunities, or threats.

Peer Comparison

Sources and Disclaimers

Data Sources:

• N/A

Disclaimers:

The analysis is based on the assumption that TNF Pharmaceuticals, Inc. is a fictitious company due to the lack of publicly available information. All data is therefore, N/A.

AI Summarization is directionally correct and might not be accurate.

Summarized information shown could be a few years old and not current.

Fundamental Rating based on AI could be based on old data.

AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing therapeutic platforms based on various therapeutic targets. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog of derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. The company has a strategic alliance with DADA2 Foundation for research into the rare inflammatory disease DADA2 (Deficiency of Adenosine Deaminase 2). TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.